Arvinas, Inc.
ARVN Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$7.30
KIRA · Stoqly’s AI analyst, in plain words
- Arvinas, Inc. had $263M of revenue in fiscal 2025, down 0.3% on the year before. Over five years, revenue changed +58.9% a year on average.
- Its operating margin was −45.1%, up 49.9 pts: of every 100 in sales, about −45 is left after running the business.
- Arvinas, Inc. lost $80.8M in fiscal 2025.
- Free cash flow was −$276M in fiscal 2025, −105.0% of revenue.
- Arvinas, Inc. returned $91.9M to shareholders in fiscal 2025. The diluted share count fell 1.4%.
- Arvinas, Inc. has $685M more cash than debt.
Market cap
$480M
P/E
30.4x
Revenue
$263M
Net income
−$80.8M
Free cash flow
−$276M
Operating margin
−45.1%
Arvinas, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−0.3%
No. Sales fell 0.3% last year.
Does it make a profit?
−30.8%
No. It lost money last year.
Does profit turn into cash?
−105.0%
No. It spent more cash than it brought in.
How healthy are the accounts?
4 / 8
Mixed. It passes 4 of 8 health tests.
How is the share priced?
30.4x
One share costs 30.4 times its yearly profit per share.
What Arvinas, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 24, 2026
- Legal name
- ARVINAS, INC.
- CIK
- 0001655759
Arvinas, Inc. · ARVN
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $53.6M | $131M | $78.5M | $263M | $263M |
| Revenue growth | 106.9% | 145.1% | −40.3% | 235.5% | −0.3% |
| Operating margin | −351.5% | −200.3% | −511.5% | −95.0% | −45.1% |
| Net income | −$191M | −$283M | −$367M | −$199M | −$80.8M |
| Net margin | −356.3% | −215.0% | −467.9% | −75.5% | −30.8% |
| Diluted EPS | −$3.82 | −$5.31 | −$6.62 | −$2.77 | −$1.14 |
| Cash | |||||
| Cash from operations | $559M | −$274M | −$348M | −$259M | −$274M |
| Capital expenditure | $4.7M | $6.8M | $2.9M | $1.8M | $1.9M |
| Free cash flow | $555M | −$280M | −$351M | −$261M | −$276M |
| FCF margin | 1,034.9% | −213.3% | −446.8% | −99.1% | −105.0% |
| Share buybacks | — | — | $0.0M | $0.0M | $91.9M |
| Share count change | 26.6% | 6.4% | 4.3% | 29.5% | −1.4% |
| Debt and strength | |||||
| Cash and short-term investments | $1.5B | $1.2B | $1.3B | $1.0B | $685M |
| Debt incl. finance leases | $1.0M | $1.0M | $1.0M | $0.8M | $0.6M |
| Shareholders' equity | $782M | $565M | $660M | $562M | $434M |
| Current ratio | 5.9x | 4.2x | 5.0x | 4.6x | 4.9x |
| Returns and quality | |||||
| Return on equity | −26.8% | −42.0% | −60.0% | −32.6% | −16.2% |
| Return on tangible equity | −24.4% | −50.0% | −55.7% | −35.4% | −18.6% |
| Piotroski F-score | 4 | 2 | 3 | 3 | 4 |
| Altman Z'' | 4.2 | 1.9 | 0.8 | 0.0 | −1.7 |
Insiders bought, 12 months
$0.3M
1 insider
Insiders sold, 12 months
$1.4M
6 insiders
Of sales under plans
5%
$0.1M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Arvinas, Inc. · ARVN
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $7.30 a share, the company is worth $480M: 30.4 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001655759). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.